Corticosteroids in acute respiratory distress syndrome
Improving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in t...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2005-02-01
|
Series: | Brazilian Journal of Medical and Biological Research |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003 |
id |
doaj-5036b3b53c9249d29bfc0742adf1c32d |
---|---|
record_format |
Article |
spelling |
doaj-5036b3b53c9249d29bfc0742adf1c32d2020-11-24T20:57:56ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2005-02-0138214715910.1590/S0100-879X2005000200003Corticosteroids in acute respiratory distress syndromeA.B.S. FernandesW.A. ZinP.R.M. RoccoImproving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in the armamentarium against acute respiratory distress syndrome. Corticosteroid therapy has been studied in three situations: prevention in high-risk patients, early treatment with high-dose, short-course therapy, and prolonged therapy in unresolving cases. There are differences between the corticosteroid trials of the past and recent trials: today, treatment starts 2-10 days after disease onset in patients that failed to improve; in the past, the corticosteroid doses employed were 5-140 times higher than those used now. Additionally, in the past treatment consisted of administering one to four doses every 6 h (methylprednisolone, 30 mg/kg) versus prolonging treatment as long as necessary in the new trials (2 mg kg-1 day-1 every 6 h). The variable response to corticosteroid treatment could be attributed to the heterogeneous biochemical and molecular mechanisms activated in response to different initial insults. Numerous factors need to be taken into account when corticosteroids are used to treat acute respiratory distress syndrome: the specificity of inhibition, the duration and degree of inhibition, and the timing of inhibition. The major continuing problem is when to administer corticosteroids and how to monitor their use. The inflammatory mechanisms are continuous and cyclic, sometimes causing deterioration or improvement of lung function. This article reviews the mechanisms of action of corticosteroids and the results of experimental and clinical studies regarding the use of corticosteroids in acute respiratory distress syndrome.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003Acute respiratory distress syndromeCollagenCytokineMethylprednisoloneExperimental modelsClinical trials |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
A.B.S. Fernandes W.A. Zin P.R.M. Rocco |
spellingShingle |
A.B.S. Fernandes W.A. Zin P.R.M. Rocco Corticosteroids in acute respiratory distress syndrome Brazilian Journal of Medical and Biological Research Acute respiratory distress syndrome Collagen Cytokine Methylprednisolone Experimental models Clinical trials |
author_facet |
A.B.S. Fernandes W.A. Zin P.R.M. Rocco |
author_sort |
A.B.S. Fernandes |
title |
Corticosteroids in acute respiratory distress syndrome |
title_short |
Corticosteroids in acute respiratory distress syndrome |
title_full |
Corticosteroids in acute respiratory distress syndrome |
title_fullStr |
Corticosteroids in acute respiratory distress syndrome |
title_full_unstemmed |
Corticosteroids in acute respiratory distress syndrome |
title_sort |
corticosteroids in acute respiratory distress syndrome |
publisher |
Associação Brasileira de Divulgação Científica |
series |
Brazilian Journal of Medical and Biological Research |
issn |
0100-879X 1414-431X |
publishDate |
2005-02-01 |
description |
Improving the course and outcome of patients with acute respiratory distress syndrome presents a challenge. By understanding the immune status of a patient, physicians can consider manipulating proinflammatory systems more rationally. In this context, corticosteroids could be a therapeutic tool in the armamentarium against acute respiratory distress syndrome. Corticosteroid therapy has been studied in three situations: prevention in high-risk patients, early treatment with high-dose, short-course therapy, and prolonged therapy in unresolving cases. There are differences between the corticosteroid trials of the past and recent trials: today, treatment starts 2-10 days after disease onset in patients that failed to improve; in the past, the corticosteroid doses employed were 5-140 times higher than those used now. Additionally, in the past treatment consisted of administering one to four doses every 6 h (methylprednisolone, 30 mg/kg) versus prolonging treatment as long as necessary in the new trials (2 mg kg-1 day-1 every 6 h). The variable response to corticosteroid treatment could be attributed to the heterogeneous biochemical and molecular mechanisms activated in response to different initial insults. Numerous factors need to be taken into account when corticosteroids are used to treat acute respiratory distress syndrome: the specificity of inhibition, the duration and degree of inhibition, and the timing of inhibition. The major continuing problem is when to administer corticosteroids and how to monitor their use. The inflammatory mechanisms are continuous and cyclic, sometimes causing deterioration or improvement of lung function. This article reviews the mechanisms of action of corticosteroids and the results of experimental and clinical studies regarding the use of corticosteroids in acute respiratory distress syndrome. |
topic |
Acute respiratory distress syndrome Collagen Cytokine Methylprednisolone Experimental models Clinical trials |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200003 |
work_keys_str_mv |
AT absfernandes corticosteroidsinacuterespiratorydistresssyndrome AT wazin corticosteroidsinacuterespiratorydistresssyndrome AT prmrocco corticosteroidsinacuterespiratorydistresssyndrome |
_version_ |
1716787173445861376 |